Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Masimo's mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.4 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,5 improve CCHD screening in newborns,6 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.7-10 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,11 and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S. News and World Report Best Hospitals Honor Roll.12 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient's physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo's family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView :60™, and Masimo SafetyNet™.
52 Discovery
Irvine, California 92618-3105
Phone: 19492977000
www.masimo.com
Masimo Corp (MASI) Q2 2024 Earnings Call Transcript Highlights: Strong Healthcare Revenue Growth and Strategic Initiatives
Second Quarter 2024 Highlights: Consolidated revenue was $496.3 million; Healthcare revenue was $343.9 million; Non-healthcare revenue was $152.4 million; GAAP net income per diluted share was $0.29; and Non-GAAP net income per diluted share was $0.86. IRVINE, Calif.–(BUSINESS WIRE)–Masimo Corporation (Nasdaq: MASI) today announced its financial results for the second quarter ended June 29, 2024. […] L''articolo Masimo Reports Second Quarter 2024 Financial Results è un contenuto originale di 01net .
Masimo Corporation (NASDAQ:NASDAQ:MASI) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ETCompany ParticipantsEli Kammerman - VP of Business…
Masimo (MASI) has provided an announcement. Upcoming on August 6, 2024, the CFO of the Company will provide a detailed overview of the financial pe…
No summary available.
https://www.investing.com/news/company-news/masimo-study-shows-rpm-reduces-hospital-readmissions-postsurgery-93CH-3542202
Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in the Journal of Orthopaedics in which Dr. Michael DeRogatis and colleagues at St. Luke’s University Health Network (SLUHN) in Pennsylvania, joined by researchers at several additional institutions, evaluated the impact of remote patient monitoring (RPM) using Masimo SafetyNet and a hospital’s virtual response Jetzt den vollständigen Artikel lesen
Billionaire Bill Ackman Owns 37% Of This Company That Most Investors Have Never Heard Of (The Motley Fool) II Names AQR’s Cliff Asness And Wellesley’s Debby Kuenstner Lifetime Award Winners (Institutional Investor) Complaint Against Let’s Go Washington Could End Up Being Sent To AG’s OfficeFree (The Columbian) Masimo CEO, Directors Sued by Politan for Pushing […]